RPR early access program for Rilutek will treat 10,000 patients worldwide prior to approval.
Executive Summary
RPR PROVIDING RILUTEK TO 10,000 ALS PATIENTS WORLDWIDE in the company's early access program prior to approval of the drug. The program for patients with amyotrophic lateral sclerosis (Lou Gehrig's disease), announced by Rhone-Poulenc Rorer on June 22, will begin by registering patients through July 20. On July 24, over 1,000 patients will be selected to receive initial treatment with Rilutek (riluzole) gratis through a computerized random selection process.